Tecentriq and Pleurisy - a phase IV clinical study of FDA data

Summary:

Pleurisy is reported as a side effect among people who take Tecentriq (atezolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Avastin, and have Hepatocellular carcinoma.

The phase IV clinical study analyzes which people have Pleurisy when taking Tecentriq. It is created by eHealthMe based on reports of 12,792 people who have side effects when taking Tecentriq from the FDA, and is updated regularly.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

What is Pleurisy?

Pleurisy (inflammation of the pleurae, which causes pain when breathing) is found to be associated with 817 drugs and 1,140 conditions by eHealthMe. Check the latest studies of Pleurisy.

On Jul, 10, 2026

12,792 people reported to have side effects when taking Tecentriq.
Among them, 12 people (0.09%) have Pleurisy.

Among these 12 people:

How long have people been on Tecentriq when they have Pleurisy? *

What is the gender of people who have Pleurisy when taking Tecentriq? *

female: 8.33 %
male: 91.67 %

What is the age of people who have Pleurisy when taking Tecentriq? *

What are other drugs people take besides Tecentriq? *

What are other side effects people have besides Pleurisy? *

Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 16.67%
Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung): 2 people, 16.67%
Pneumonia Bacterial (pneumonia associated with bacterial infection): 2 people, 16.67%
Pleural Effusion (water on the lungs): 2 people, 16.67%
Fever: 2 people, 16.67%
Thyroiditis (inflammation of thyroid gland): 1 person, 8.33%
Eosinophilia (eosinophil count in the peripheral blood exceeds): 1 person, 8.33%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 8.33%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 8.33%
Cardiac Failure Acute: 1 person, 8.33%

What are the existing conditions these people have? *

Hepatocellular Carcinoma (liver cancer): 5 people, 41.67%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 33.33%
Lung Cancer - Small Cell (lung cancer): 1 person, 8.33%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%
Gastritis (inflammation of stomach): 1 person, 8.33%
Dyslipidaemia (abnormal amount of lipids): 1 person, 8.33%
Bronchial Carcinoma (lung cancer): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Tecentriq and have Pleurisy?

- Check whether Pleurisy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tecentriq:

Tecentriq (12,796 reports)

Pleurisy treatments and more:

Pleurisy (9,090 reports)

Browse all side effects of Tecentriq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pleurisy:

Pleurisy (817 drugs)

Browse all the conditions that are associated with Pleurisy:

Pleurisy (1,140 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on atezolizumab (the active ingredients of Tecentriq) and Tecentriq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.